411 related articles for article (PubMed ID: 33579845)
1. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.
Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T
J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845
[TBL] [Abstract][Full Text] [Related]
2. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H
Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732
[TBL] [Abstract][Full Text] [Related]
3. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
4. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
[TBL] [Abstract][Full Text] [Related]
5. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
6. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
7. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.
Haggerty T; Credle J; Rodriguez O; Wills J; Oaks AW; Masliah E; Sidhu A
Eur J Neurosci; 2011 May; 33(9):1598-610. PubMed ID: 21453448
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
[TBL] [Abstract][Full Text] [Related]
9. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
10. Adeno-Associated Virus-Mediated Immunotherapy Based on Bispecific Tandem scFv for Alzheimer's Disease.
Qian L; Bian W; Wang D; Ming Z; Zhang Y; Zhang L; Fu L
J Alzheimers Dis; 2023; 93(2):435-448. PubMed ID: 37038816
[TBL] [Abstract][Full Text] [Related]
11. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
[TBL] [Abstract][Full Text] [Related]
13. The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice.
Gratuze M; Josset N; Petry FR; Pflieger M; Eyoum Jong L; Truchetti G; Poitras I; Julien J; Bezeau F; Morin F; Samadi P; Cicchetti F; Bretzner F; Planel E
Brain Res; 2019 May; 1711():106-114. PubMed ID: 30641037
[TBL] [Abstract][Full Text] [Related]
14. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.
Dejanovic B; Huntley MA; De Mazière A; Meilandt WJ; Wu T; Srinivasan K; Jiang Z; Gandham V; Friedman BA; Ngu H; Foreman O; Carano RAD; Chih B; Klumperman J; Bakalarski C; Hanson JE; Sheng M
Neuron; 2018 Dec; 100(6):1322-1336.e7. PubMed ID: 30392797
[TBL] [Abstract][Full Text] [Related]
15. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
[TBL] [Abstract][Full Text] [Related]
16. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.
Li X; James S; Lei P
J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562
[TBL] [Abstract][Full Text] [Related]
17. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
18. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology.
Dabir DV; Trojanowski JQ; Richter-Landsberg C; Lee VM; Forman MS
Am J Pathol; 2004 Jan; 164(1):155-66. PubMed ID: 14695329
[TBL] [Abstract][Full Text] [Related]
19. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
Muntané G; Dalfó E; Martinez A; Ferrer I
Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
